The Journal of Urology
Volume 179, Issue 2 , Pages 610-615, February 2008

Effect of Saw Palmetto Soft Gel Capsule on Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Randomized Trial in Shanghai, China

  • Rong Shi

      Affiliations

    • School of Public Health, Shanghai, People’s Republic of China
  • ,
  • Qiungwen Xie

      Affiliations

    • School of Public Health, Shanghai, People’s Republic of China
  • ,
  • X. Gang

      Affiliations

    • School of Public Health, Shanghai, People’s Republic of China
  • ,
  • Jing Lun

      Affiliations

    • Ren Ji Hospital, Shanghai, People’s Republic of China
  • ,
  • Life Cheng

      Affiliations

    • Shanghai Jiao Tong University and Za Pu Community Health Service Center of Shanghai, Shanghai, People’s Republic of China
  • ,
  • Allan Pantuck

      Affiliations

    • Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California
  • ,
  • Jianyu Rao

      Affiliations

    • Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California
    • Corresponding Author InformationCorrespondence: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, 10833 Le Conte Ave., Los Angeles, California 90095 (telephone: 01-310-794-1567).

Received 4 May 2007 published online 13 December 2007.

Purpose

We determined the effect of Prostataplex™ in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Materials and Methods

A total of 92 Chinese men between 49 and 75 years old with lower urinary tract symptoms were randomly assigned in this double-blind, placebo controlled trial. The 46 patients in the intervention group were given 2 Prostataplex soft gels daily for 12 weeks, while the 46 in the control group were given 2 placebo soft gels for the same time.

Results

The treated and control groups appeared to have more than a 95% compliance rate, as judged by counting the remaining pills in the bottle collected at the end of trial months 1 to 3. After 12 weeks of intervention the mean ± SD maximum urinary flow rate was significantly higher in the treatment group than in the control group (14.07 ± 2.56 vs 11.74 ± 1.23 ml per second, p <0.001), while relative urinary resistance was significantly lower in the treatment group than in the control group (2.35 ± 0.83 vs 3.02 ± 1.18, p = 0.002). While there was no significant difference in mean prostate volume or International Prostate Symptom Score between the 2 groups, 18 of 46 patients (39.1%) in the treatment group showed an International Prostate Symptom Score improvement (decrease of 3 or greater) after intervention, whereas only 1 of 46 (2.2%) in the control group showed an International Prostate Symptom Score improvement (chi-square test p <0.001).

Conclusions

Prostataplex may have short-term effects in improving symptoms and objective measures in Chinese men with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Key Words: Serenoa, prostate, prostatic hyperplasia, urination disorders

Abbreviations and Acronyms: BPH, benign prostatic hyperplasia, BUN, blood urea nitrogen, DRE, digital rectal examination, I-PSS, International Prostate Symptom Score, LUTS, lower urinary tract symptoms, MFR, maximum flow rate, RUR, relative urinary resistance

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 For another article on a related topic see page 770.

 Study received approval from the research ethics committee at each institution.

 Supported by the Journal of Longevity.

PII: S0022-5347(07)02532-3

doi:10.1016/j.juro.2007.09.032

Refers to article:

  • Mechanisms by Which a Phytotherapeutic Drug Influences Bladder Activity in Rats , 14 December 2007

    Kimio Sugaya, Saori Nishijima, Shinsuke Tasaki, Katsumi Kadekawa, Minoru Miyazato, Yoshihide Ogawa
    The Journal of Urology February 2008 (Vol. 179, Issue 2, Pages 770-774)

The Journal of Urology
Volume 179, Issue 2 , Pages 610-615, February 2008